Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 Presenter Profiles.

MONTE CARLO, Monaco -- Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 takes place May 15-16 in Monte Carlo.

For in-depth information about the event visit http://www.rodmanandrenshaw.com/Conferences.asp?CID=conf9.

Below are profiles from Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 presenters; breaking news releases are available at http://www.tradeshownews.com, Business Wire's event news resource.

Business Wire is the official news wire service for Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006.

Company:                          Active Biotech AB
Ticker Symbol & Exchange:         ACTI.SE SEK
Investor Relations Contact:       Cecilia Hofvander
Investor Relations Contact Phone: [phone]
Web:                              www.activebiotech.com
Date of Presentation:             May 16

Active Biotech AB is a biotechnology company focusing on research and
development of pharmaceuticals. Active Biotech has a strong R&D
portfolio with pipeline products focused on autoimmune/inflammatory
diseases and cancer. Most advanced projects are laquinimod, an orally
administered small molecule with unique immunomodulatory properties
for the treatment of multiple sclerosis, as well as ANYARA for use in
cancer immunotherapy with the primary indication non-small cell lung
cancer. Further key projects in clinical development comprise the
three orally administered compounds TASQ for prostate cancer 57-57 for
SLE and RhuDex(R) for RA

Company:                          Advancis Pharmaceutical Corp.
Ticker Symbol & Exchange:         AVNC: NASDAQ
Investor Relations Contact:       Bob Bannon
Investor Relations Contact Phone: [phone]
Web:                              www.advancispharm.com
Date of Presentation:             05/16/2006

Advancis is a pharmaceutical company focused on developing and
commercializing anti-infective drug products that fulfill unmet
medical needs in the treatment of infectious disease. Based on the
Company's finding that bacteria exposed to antibiotics in sequential
bursts, or pulses, are killed more efficiently than those exposed to
standard treatment regimens, Advancis has developed a proprietary,
once-a-day pulsatile delivery technology for antibiotics and other
anti-infectives called PULSYS(TM). The Company has an ongoing Phase
III clinical trial for an Amoxicillin PULSYS product, is currently
selling the Keflex brand of cephalexin, and is exploring a once-daily
pulsatile formulation of Keflex.

Company:                          AEterna Zentaris Inc.
Ticker Symbol & Exchange:         NASDAQ:AEZS TSX:AEZ
Investor Relations Contact:       Ms. Jenene Thomas
Investor Relations Contact Phone: [phone]
Web:                              www.aeternazentaris.com
Date of Presentation:             May 15, 2006

AEterna Zentaris Inc. (TSX:AEZ, NASDAQ:AEZS) is a growing global
biopharmaceutical company focused on oncology and endocrine therapy
with proven expertise in drug discovery, development and
commercialization.

AEterna Zentaris also owns 48.40% of the equity of Atrium
Biotechnologies Inc. (TSX:ATB.sv) and 64.9% of its voting rights.
Atrium is a developer, manufacturer and marketer of science-based
products for the cosmetics, pharmaceutical, chemical and nutritional
industries.

Company:                          Altea Therapeutics Corporation
Investor Relations Contact:       Steven P. Damon
Investor Relations Contact Phone: [phone]
Web:                              http://www.alteatherapeutics.com

Altea Therapeutics is a privately-held pharmaceutical company
developing advanced transdermal patches that painlessly and
efficiently deliver sustained therapeutic levels of proteins and
water-soluble drugs.

The Company is conducting human clinical trials in the US on two major
product innovations: (i) hydromorphone and fentanyl patches for the
rapid management of moderate to severe pain; and (ii) patches for
providing basal levels of insulin for 12- or 24-hours thus addressing
the needs of type 1 or type 2 diabetics.

Furthermore, it is also conducting feasibility studies on using the
PassPort(TM) System for the delivery of apomorphine (Parkinson's
disease) and vaccines (disease prevention).

Company:                          Alteon Inc.
Ticker Symbol & Exchange:         AMEX:  ALT
Investor Relations Contact:       Susan Pietropaolo
Investor Relations Contact Phone: [phone]
Web:                              www.alteon.com
Date of Presentation:             May 15, 2006

Alteon recently announced a definitive merger agreement with
privately-held HaptoGuard, Inc., and the granting of certain royalty
and negotiation rights to Genentech, Inc. as part of the restructuring
of Genentech's preferred stock position in Alteon. Alteon and
HaptoGuard have complementary products under development in
cardiovascular diseases and diabetes, including two Phase 2
clinical-stage compounds. Data is expected around year-end 2006 from
two Phase 2 trials of HaptoGuard's BXT-51072 for reduction of
mortality in post-myocardial infarction patients with diabetes.
Alteon's alagebrium, which has been shown to improve cardiac function
including the ability to significantly reduce left ventricular mass,
is being developed for heart failure.

Company:                          Amarin Corporation
Ticker Symbol & Exchange:         NASDAQ (AMRN)
Investor Relations Contact:       Rick Stewart, CEO
Investor Relations Contact Phone: [phone]
Web:                              www.amarincorp.com
Date of Presentation:             May 15, 2006

Amarin is a neuroscience company focused on the research, development
and commercialization of novel drugs for the treatment of central
nervous system disorders. Miraxion, Amarin's lead development
compound, is in Phase III development for Huntington's disease, Phase
II development for depressive disorders and preclinical development
for Parkinson's disease. Miraxion for Huntington's disease is being
developed under a Special Protocol Assessment agreed with the US Food
and Drug Administration ("FDA"), has been granted fast track
designation by the FDA and has received orphan drug designation in the
US and Europe.

Company:                          Ambrilia Biopharma Inc.
Ticker Symbol & Exchange:         TSX:AMB
Investor Relations Contact:       Julie M. Thibodeau
Investor Relations Contact Phone: [phone] ext. 235
Web:                              www.ambrilia.com
Date of Presentation:             May 16, 2006 - 3:40-4:00 pm

Ambrilia Biopharma Inc. (TSX:AMB) is a biopharmaceutical company
developing innovative therapeutics in the fields of oncology and
infectious diseases. Ambrilia's product portfolio includes mid to
early-stage products (PPL-100, PCK3145, TVT-Dox, SPC3) and two
specialty generics (Octreotide and Goserelin), the first of which is
late-stage and value-added. With these products, Ambrilia Biopharma
expects to accelerate its path to profitability by generating
potential revenues through U.S. and European sales of Octreotide and
European sales of Goserelin. Ambrilia's head office, Research and
Development and Manufacturing facilities are located in Montreal with
a regional office in France. Ambrilia's common shares are traded on
the Toronto Stock Exchange under the ticker symbol AMB

Company:                          Antares Pharma, Inc.
Ticker Symbol & Exchange:         Amex: AIS
Investor Relations Contact:       Stephanie M. Baldwin
Investor Relations Contact Phone: [phone]
Web:                              www.antarespharma.com
Date of Presentation:             May 15, 2006

Antares Pharma is a specialized pharma product development company
focused on developing patented drug delivery platforms including its
recently announced TecTix(TM)system for topical and transmucosal
delivery, ATD(TM) Advanced Transdermal Delivery system, Easy Tec(TM)
fast-melt oral tablets, disposable mini-needle injection systems
(Vibex(TM)), and reusable needle-free injection systems (VISION(R) and
Valeo(TM)).

Company:                          Arbios Systems, Inc.
Ticker Symbol & Exchange:         OTCBB: ABOS
Investor Relations Contact:       Paula Schwartz
Investor Relations Contact Phone: Rx Communications Group,
                                  917-322-2216
Web:                              http://www.arbios.com
Date of Presentation:             May 15, 2006, 11:05am Eastern Time

Arbios Systems, Inc. is developing proprietary medical devices and
cell-based therapies to enhance the survival of the millions of
patients who experience, or are at risk of, life threatening episodes
of liver failure.

Arbios' pipeline includes the SEPET(TM) Liver Assist Device, currently
demonstrating favorable outcomes in a U.S. clinical feasibility trial
in patients experiencing acute exacerbation of chronic liver disease,
and the HepatAssist(TM) Cell-Based Liver Support System, combining
blood detoxification with liver cell therapy to provide replacement of
whole liver function. HepatAssist(TM) has been shown in a Phase II-III
clinical trial to enhance survival of acute liver failure patients.

Company:                          AVANT Immunotherapeutics, Inc.
Ticker Symbol & Exchange:         NASDAQ: AVAN
Investor Relations Contact:       Paula Freeman
Investor Relations Contact Phone: [phone]
Web:                              www.avantimmune.com
Date of Presentation:             May 15, 2005

AVANT Immunotherapeutics, Inc. discovers and develops innovative
vaccines and therapeutics that harness the human immune system to
prevent and treat disease. AVANT has three products on the market and
six in clinical development. These include TP10 to reduce tissue
damage associated with cardiac bypass surgery and a novel vaccine for
cholesterol management. AVANT is developing a broad pipeline of
vaccines for biodefense, travelers, global health, and pandemic flu
needs based on its rapid-protecting, single-dose, temperature-stable
vaccine technology for oral delivery. AVANT has received $50M over the
last 12 months in financings from Paul Royalty Fund for future
Rotarix(R) royalty revenues.

Company:                          Bentley Pharmaceuticals, Inc.
Ticker Symbol & Exchange:         NYSE:  BNT
Investor Relations Contact:       Tara Spiess
Investor Relations Contact Phone: [phone]
Web:                              www.bentleypharm.com
Date of Presentation:             May 15, 2006

Bentley Pharmaceuticals, Inc. is a vertically integrated specialty
pharmaceutical company with a growing, profitable international
generic business and two proprietary drug-delivery platform
technologies, which have broad potential to replace injections and
improve health outcomes. Bentley's revenues and profits come primarily
from the company's growing portfolio of generic pharmaceuticals,
currently marketed in the EU. Over the past five years, Bentley's most
advanced drug-delivery technology, CPE-215, has already led to the
development of a marketed product, TESTIM, a topical testosterone gel
licensed to Auxilium Pharmaceuticals. Clinical trials are under way
for the development of intranasal administration of insulin.

Company:                          BioBalance Corp.
Ticker Symbol & Exchange:         BBAL: OTCBB
Investor Relations Contact:       Simon Fischer
Investor Relations Contact Phone: [phone]
Web:                              www.biobalance.com
Date of Presentation:             May 16, 2006

BioBalance is a biopharmaceutical company focused on the development
of novel treatments for gastrointestinal disorders that are poorly
addressed by current therapies. These include pouchitis, Irritable
Bowel Syndrome, Crohn's disease, ulcerative colitis, C. difficile
infections and celiac disease. The company's lead product, PROBACTRIX
(R), is a proprietary strain of non-pathogenic E.coli M17 bacteria
that restores the microbial balance to the digestive system. Prior
overseas studies have confirmed that this product works across a wide
range of GI disorders and should be viewed as a platform technology.
On March 24, 2006, BioBalance received FDA approval to begin phase II
clinical trials.

Company:                          BioMarin Pharmaceutical Inc.
Ticker Symbol & Exchange:         Nasdaq/SWX:  BMRN
Investor Relations Contact:       Joshua Grass
Investor Relations Contact Phone: [phone]
Web:                              www.BMRN.com
Date of Presentation:             Monday, May 15, 2006

BioMarin develops and commercializes innovative biopharmaceuticals for
serious diseases and medical conditions. The company's product
portfolio is comprised of two approved products and multiple
investigational product candidates. Approved products include
Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a
product wholly developed and commercialized by BioMarin, and
Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a
product which BioMarin developed through a 50/50 joint venture with
Genzyme Corporation. Additionally, BioMarin has rights to receive
payments and royalties related to Orapred(R) (prednisolone sodium
phosphate oral solution). Investigational product candidates include
Phenoptin(TM) (sapropterin dihydrochloride), a Phase 3 product
candidate for the treatment of phenylketonuria (PKU).

Company:                          Bioniche Life Sciences Inc.
Ticker Symbol & Exchange:         TSX: BNC
Investor Relations Contact:       Jennifer Shea
Investor Relations Contact Phone: [phone]
Web:                              www.Bioniche.com
Date of Presentation:             Tuesday, May 16, 2006

Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary products for
human and animal health markets worldwide. The fully-integrated
company employs approximately 185 skilled personnel and has three
principal operating divisions: Human Health, Animal Health, and Food
Safety. The Company's primary goal is to develop proprietary cancer
therapies supported by revenues from marketed products in these three
segments. The first of these therapies is for the treatment of bladder
cancer. Recruitment for two FDA-approved Phase III clinical trials
will begin later in 2006.

Company:                          BioSante Pharmaceuticals, Inc.
Ticker Symbol & Exchange:         BPA--Amex
Investor Relations Contact:       Phillip Donenberg
Investor Relations Contact Phone: [phone] ext 101
Web:                              www.biosantepharma.com
Date of Presentation:             April 11, 2006

BioSante is developing a pipeline of hormone therapy products to treat
both men and women. These hormone therapy products are gel
formulations for transdermal administration that deliver bioidentical
estradiol and testosterone. BioSante's lead products include
Bio-E-Gel(TM) (transdermal estradiol gel) for the treatment of women
with menopausal symptoms, and LibiGel(TM) (transdermal testosterone
gel) for the treatment of female sexual dysfunction (FSD). A Bio-E-Gel
new drug application (NDA) was submitted to the FDA on February 16,
2006. The current market in the U.S. for estrogen and testosterone
products is approximately $2.5 billion. The company also is developing
its calcium phosphate nanotechnology (CaP) for novel vaccines,
including biodefense vaccines for toxins such as anthrax and ricin,
and drug delivery systems.

Company:                          BioSphere Medical, Inc.
Ticker Symbol & Exchange:         BSMD
Investor Relations Contact:       Maura Gedid
Investor Relations Contact Phone: [phone]
Web:                              www.biospheremed.com
Date of Presentation:             May 15, 2006

BioSphere Medical applies its proprietary, bioengineered microsphere
technology to a variety of medical therapies through the use of
embolotherapy. Embolotherapy works by reducing blood flow to targeted
areas of the body. The Company is the world leader in the growing
Uterine Fibroid Embolization market, and is also active in the
treatment of liver cancer using embolization.

Company:                          Boston Life Sciences, Inc.
Ticker Symbol & Exchange:         NASDAQ: BLSI
Investor Relations Contact:       Sharon Correia
Investor Relations Contact Phone: [phone]
Web:                              www.bostonlifesciences.com
Date of Presentation:             5/15/2006 from 3:20pm - 3:40pm

Boston Life Sciences is a biopharmaceutical company engaged in the
research and development of diagnostic and therapeutic products for
CNS disorders.

Its Molecular Imaging Program includes ALTROPANE(R) molecular imaging
agent, currently in Phase III development for diagnosing Parkinson's
disease, and in Phase II development for diagnosing ADHD. BLSI also
has a preclinical development program focused on next generation
imaging agents for diagnosing CNS disorders using SPECT, PET and MRI
imaging. In the Company's Axon Regeneration Program, INOSINE is aimed
at functional recovery in stroke. BLSI's DAT blocker program is aimed
at symptom management and modification of disease progression in PD
and is in preclinical development.

Company:                          Cellerant Therapeutics, Inc.
Investor Relations Contact:       Bruce Cohen, President & CEO
Investor Relations Contact Phone: [phone]
Web:                              http://www.cellerant.com
Date of Presentation:             5/16/05

Cellerant Therapeutics, Inc. is a clinical-stage biotechnology company
developing curative treatments for cancer and hematologic disorders
using products derived from its knowledge of the human hematopoietic
(blood forming) system and its ability to produce highly purified
hematopoietic cell populations. The Company's commercial strategy is
to develop (1) A cell purification platform (CLT-001) that will enable
highly purified stem cell transplant-based therapy for the treatment
of genetic blood disorders and cancer; (2) An off-the-shelf cell-based
product (CLT-008) with multiple indications in the treatment of
neutropenic patients; and (3) Antibody therapeutics targeting
hematologic cancer stem cells.

Company:                          Ceragenix
Ticker Symbol & Exchange:         CGXP
Investor Relations Contact:       Robert Stanislaro
Investor Relations Contact Phone: [phone]
Web:                              www.ceragenix.com
Date of Presentation:             May 15 at 5:15 EDT

Ceragenix Pharmaceuticals, Inc. (OTCBB: CGXP - News) is a
biopharmaceutical company that discovers, develops and commercializes
novel anti-infective drugs based on its proprietary class of
compounds, Ceragenins(TM) (or CSAs). Active against a broad range of
gram positive and negative bacteria, these agents are being developed
as anti-infective medical device coatings (Ceracides(TM)) and as
therapeutics for antibiotic-resistant organisms. Ceragenix further
owns exclusive rights to Barrier Repair Technology for the treatment
of dermatological disorders including atopic dermatitis, neonatal skin
disorders and others. Ceragenix's patented Barrier Repair Technology,
invented by Dr. Peter Elias and licensed from the University of
California, is the platform for the development of two prescription
topical creams--EpiCeram(R) and NeoCeram(R).

Company:                          ChemGenex Pharmaceuticals Limited
Ticker Symbol & Exchange:         NASDAQ: CXSP
Web:                              www.chemgenex.com
Date of Presentation:             May 15, 2006

ChemGenex Pharmaceuticals is a pharmaceutical development company
dedicated to improving the lives of patients by developing
therapeutics in the areas of oncology, diabetes, obesity, and
depression. ChemGenex's lead compound, Ceflatonin(R)
(homoharringtonine or HHT), is currently in phase 2 clinical trials
for a range of leukemias and Quinamed(R) (amonafide dihydrochloride),
is in phase 2 clinical trials for prostate, breast and ovarian
cancers. The company has a significant portfolio of cancer, diabetes,
obesity and depression programs, several of which have been partnered
with international pharmaceutical companies.

Company:                          Ciphergen Biosystems, Inc.
Ticker Symbol & Exchange:         CIPH Nasdaq
Investor Relations Contact:       Sue Carruthers
Investor Relations Contact Phone: [phone]
Web:                              www.ciphergen.com
Date of Presentation:             Monday May 15, 3:40 p.m.

Ciphergen is dedicated to the discovery of protein biomarkers and
panels of biomarkers and their development into protein molecular
diagnostic tests that improve patient care; and to providing
collaborative R&D services through its Biomarker Discovery Center(R)
laboratories for biomarker discovery for new diagnostic tests as well
as pharmacoproteomic services for improved drug toxicology, efficacy
and theranostic assays. Ciphergen develops, manufactures and markets a
family of ProteinChip(R) Systems and services for clinical, research
and process proteomics applications. ProteinChip Systems enable
protein discovery, validation, identification and assay development to
provide researchers with predictive, multi-marker assay capabilities
and a better understanding of biological function at the protein
level.

Company:                          CombinatoRx, Inc.
Ticker Symbol & Exchange:         CRXX
Investor Relations Contact:       Robert Forrester / Gina Nugent
Investor Relations Contact Phone: [phone]
Web:                              www.combinatorx.com
Date of Presentation:             Tuesday, May 16th

CombinatoRx, Inc. is a biopharmaceutical company focused on developing
new medicines built from synergistic combinations of approved drugs.
In less than six years, we have discovered and advanced into clinical
trials a portfolio of six product candidates targeting multiple
immuno-inflammatory diseases and cancer, at a total investment,
including development of our proprietary screening technology, of less
than $50 million.

We are developing our combination drugs in response to the
understanding that many diseases affect the body through multiple
biological pathways. Traditional drug discovery has focused on agents
that target a single biological pathway. We believe that by targeting
multiple pathways, our combination drug candidates may create
synergistic therapeutic effects, which could result in improved
treatments for many diseases.

Company:                          CYCLACEL PHARMACEUTICALS, INC.
Ticker Symbol & Exchange:         CYCC (NASDAQ)
Investor Relations Contact:       Tara Spiess / Andrea Romstad
Investor Relations Contact Phone: [phone]
Web:                              www.cyclacel.com
Date of Presentation:             May 15, 2006

Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company
dedicated to the discovery, development and commercialization for
oncology indications of novel, mechanism-targeted drugs that affect
the cancer cell cycle. Cyclacel's seliciclib, the leading
orally-available Cyclin Dependent Kinase inhibitor, is in Phase II
clinical trials for the treatment of non-small cell lung cancer.
Sapacitabine, an orally-available, cell cycle modulating nucleoside
analog, is in Phase I clinical trials for the treatment of cancer.
CYC116, an orally available, Aurora kinase inhibitor, is in
IND-directed preclinical development. Several additional programs are
at an earlier stage. Cyclacel operates from facilities located in New
Jersey, England and Scotland.

Company:                          CYTOGEN Corporation
Ticker Symbol & Exchange:         CYTO
Investor Relations Contact:       Christopher P. Schnittker
Investor Relations Contact Phone: [phone]
Web:                              www.cytogen.com
Date of Presentation:             Monday, May 15, 2006

Founded in 1980, Cytogen Corporation of Princeton, NJ is a
biopharmaceutical company dedicated to improving the lives of patients
with cancer by acquiring, developing and commercializing innovative
molecules targeting the sites and stages of cancer progression.
Cytogen's marketed products include QUADRAMET(R) (samarium Sm-153
lexidronam injection), PROSTASCINT(R) (capromab pendetide) kit for the
preparation of Indium In-111 capromab pendetide and SOLTAMOX(TM)
(tamoxifen citrate) in the United States. Cytogen's development
pipeline includes CYT-500, a therapeutic radiolabeled antibody
targeting PSMA.

Company:                          Cytori Therapeutics
Ticker Symbol & Exchange:         NASDAQ: CYTX
Investor Relations Contact:       Tom Baker
Investor Relations Contact Phone: [phone]
Web:                              www.cytoritx.com
Date of Presentation:             May 15, 2006

Cytori Therapeutics, Inc., is discovering and developing proprietary
cell-based therapeutics utilizing adult stem and regenerative cells
derived from adipose tissue, also known as fat. The Company's
investigational therapies target cardiovascular disease, spine and
orthopedic conditions, gastrointestinal disorders and new approaches
for aesthetic and reconstructive surgery. To facilitate processing and
delivery of adipose stem and regenerative cells, Cytori has developed
its proprietary Celution(TM) System to isolate and concentrate a
patient's own stem and regenerative cells in about an hour. This
system will dramatically improve the speed in which personalized
cell-based therapies can be delivered to patients.

Company:                          CytRx Corporation
Ticker Symbol & Exchange:         CYTR (Nasdaq)
Investor Relations Contact:       Ed Umali
Investor Relations Contact Phone: [phone] x309
Web:                              www.cytrx.com
Date of Presentation:             May 15, 2006

CytRx is a world leader in the development of high-value therapeutics
utilizing its core technologies in small molecule drugs, RNAi drug
discovery and DNA vaccines. The company's small molecule therapeutics
program involves "molecular chaperone" oral drug candidates, the first
of which is arimoclomol for the treatment of ALS (Lou Gehrig's
disease), which is currently in a Phase II trial. CytRx announced
favorable interim results from a DNA-based HIV vaccine Phase I
clinical trial, and is conducting RNAi-based drug discovery research
to identify new approaches to treat metabolic diseases. Additional
programs currently underway address obesity, type 2 diabetes,
cardiovascular disease and diabetic wound healing.

Company:                          Dyadic International, Inc.
Ticker Symbol & Exchange:         AMEX:DIL
Investor Relations Contact:       Neil Berkman, Berkman Associates
Investor Relations Contact Phone: [phone]
Web:                              www.dyadic-group.com
Date of Presentation:             May 15, 2006

Dyadic develops, manufactures and sells biological products using
proprietary fungal strains to produce enzymes and other biomaterials,
principally focused on a system for protein production based on the
patented C1 fungus.

Dyadic sells enzyme products to global customers in the textile, pulp
& paper, and animal feed industries, and is developing its C1
technology to facilitate the discovery, development and large-scale
production of human antibodies and other high-value therapeutic
proteins. Dyadic also is applying its technologies to develop and
manufacture enzymes for the conversion of agricultural byproducts like
corn stover and sugar cane bagasse into fermentable sugars that can be
used to produce ethanol.

Company:                          EntreMed, Inc.
Ticker Symbol & Exchange:         ENMD
Investor Relations Contact:       Ginny Dunn
Investor Relations Contact Phone: [phone]
Web:                              www.entremed.com
Date of Presentation:             Monday, May 15, 2006

EntreMed, Inc. is a clinical-stage pharmaceutical company focused on
developing next generation multi-mechanism oncology and
antiinflammatory drugs that target disease cells directly and the
blood vessels that nourish them. EntreMed is focused on developing
drugs that are safe and convenient, and provide the potential for
improved patient outcomes. Panzem(R) (2-methoxyestradiol or 2ME2), one
of the Company's lead drug candidates, is currently in Phase 2
clinical trials for cancer, as well as in preclinical development for
rheumatoid arthritis. MKC-1, a novel cell cycle inhibitor acquired
through the recent acquisition of Miikana Therapeutics, is also in
Phase 2 clinical trials for cancer. ENMD-1198, a novel tubulin binding
agent discovered by EntreMed, is currently in Phase 1 clinical studies
in patients with advanced cancer.

Company:                          Evotec AG
Ticker Symbol & Exchange:         EVT at FSE
Investor Relations Contact:       Anne Hennecke
Investor Relations Contact Phone: [phone]
Web:                              www.evotec.com
Date of Presentation:             15 May 2006, 12.40 pm

Evotec is an international leader in the discovery and development of
new, small-molecule drugs. In proprietary projects, Evotec specialises
in finding new treatments for diseases of the central nervous system.
Evotec has three Phase I clinical programmes: EVT 201 (GABA-A
modulator) for the treatment of insomnia and EVT 101 (subtype
selective NMDA receptor antagonist) & EVT 301 (selective and
reversible inhibitor of MAO-B), both for the treatment of Alzheimer's
disease.

In contract research, Evotec has established itself as the partner of
choice for pharmaceutical and biotechnology companies worldwide. The
Company provides innovative and often integrated solutions from drug
target to clinic through an unmatched range of capabilities, including
early stage assay development/screening through to medicinal chemistry
and drug manufacturing.

Company:                          Faust Pharmaceuticals
Investor Relations Contact:       Thomas C. Seoh
Investor Relations Contact Phone: Tel : [phone]
Web:                              www.faustpharma.com
Date of Presentation:             May 15

Faust Pharmaceuticals is a clinical-stage product company specializing
in discovering and developing drugs for nervous system diseases and
conditions.

The company's lead compound, FP0011, is a small molecule glutamate
inhibitor in Phase II for ALS and Parkinson's disease. Another
compound, FP0023, is a fetal gene activating utrophin inducer in
preparation for Phase I/II for Duchenne Muscular Dystrophy. The
company additionally has pre-clinical programs on targets such as
mGluR (metabotropic glutamate receptor), as well as a proprietary drug
discovery platform targeting GPCRs (G-Protein Coupled Receptors).

Company:                          Favrille, Inc.
Ticker Symbol & Exchange:         Nasdaq: FVRL
Investor Relations Contact:       Pete De Spain
Investor Relations Contact Phone: [phone]
Web:                              www.favrille.com
Date of Presentation:             May 15, 2006

Favrille, Inc. is a biopharmaceutical company focused on the research,
development and commercialization of targeted immunotherapies for the
treatment of cancer and other diseases of the immune system. The
Company's lead product candidate, FavId, is based upon unique genetic
information extracted from a patient's tumor. FavId is currently under
investigation in a pivotal Phase 3 clinical trial for patients with
follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL
indications. The Company is developing additional applications based
on its immunotherapy expertise and proprietary cost-effective
manufacturing technology, including a second product candidate,
FAV-201, for the treatment of T-cell lymphoma.

Company:  GammaCan International Inc
Ticker Symbol & Exchange:         OTCBB: GCAN
Investor Relations Contact:       Yaron Cherny
Investor Relations Contact Phone: [phone]
Web:                              www.GammaCan.com
Date of Presentation:             May 16th 08.40am

GammaCan (OTCBB: GCAN.OB), is an Israeli biopharmaceutical company
developing immunotherapies to treat cancer. GammaCan's treatment
platform uses intravenous immunoglobulin (IVIg). The Company is in the
process of applying for a US IND for VitiGam, GammaCan's second
generation IVIg product. GammaCan intends to conduct a PhaseI/II trial
to evaluate VitiGam in patients with stage 3 and 4 melanoma. VitiGam
is based on IVIg manufactured from plasma of donors with vitiligo, a
benign autoimmune skin condition. GammaCan scientists have
demonstrated that vitiligo derived IVIg displays potent anti-melanoma
activity model systems. GammaCan owns two issued U.S. patents and has
several patent applications pending.

Company:                          GENTA, INC.
Ticker Symbol & Exchange:         GNTA (NASDAQ)
Investor Relations Contact:       Tara Spiess/Andrea Romstad
Investor Relations Contact Phone: [phone]
Web:                              www.genta.com
Date of Presentation:             May 15, 2006

Genta is a biopharmaceutical company with a diversified product
portfolio that is focused on delivering innovative products for the
treatment of patients with cancer. A New Drug Application (NDA) has
been submitted to the U.S. Federal Drug Administration for the use of
Genasense plus fludarabine and cyclophosphamide for treatment of
patients with relapsed or refractory chronic lymphocytic leukemia
(CLL). Genta has also completed a Marketing Authorization Application
to the European Medicines Agency (EMEA) for use of Genasense plus
dacarbazine for treatment of patients with advanced melanoma. The lead
compound from Genta's Small molecule program is Ganite(R) (gallium
nitrate injection), is approved for marketing in the U.S. for
treatment of symptomatic patients with cancer related hypercalcemia
that is resistant to hydration.

Company:                          GenVec, Inc.
Ticker Symbol & Exchange:         GNVC
Investor Relations Contact:       Tricia J. Richardson
Investor Relations Contact Phone: [phone]
Web:                              www.genvec.com
Date of Presentation:             Monday, May 15, 9:25 am

GenVec, Inc. (Nasdaq: GNVC) is a biotechnology company developing
innovative therapeutics to treat cancer, sensory deterioration (loss
of vision and hearing) and heart disease. Our lead investigational
drug is TNFerade(TM) for cancer, now in Phase II/III testing in
pancreatic cancer and Phase II trials in rectal cancer and metastatic
melanoma. Our core adenovector technology is also being used to
develop vaccines for infectious diseases, including HIV and malaria,
and for anti-viral protection against foot and mouth disease. We have
three product development programs in various stages of clinical
testing.

Company:                          GPC Biotech AG
Ticker Symbol & Exchange:         FSE:GPC  /  NASDAQ:GPCB
Investor Relations Contact:       Martin Brandle
Investor Relations Contact Phone: [phone]
Web:                              www.gpc-biotech.com
Date of Presentation:             May 15, 2006

GPC Biotech AG is a biopharmaceutical company discovering and
developing new anticancer drugs. The Company's lead product candidate
- satraplatin - has achieved target enrollment in a Ph 3
registrational trial as a second-line chemotherapy treatment in
hormone-refractory prostate cancer. The U.S. FDA has granted fast
track designation to satraplatin for this indication, and GPC Biotech
has begun the rolling NDA submission process for this compound. GPC
Biotech is also developing a monoclonal antibody with a novel
mechanism, currently in Phase 1 clinical development, and has ongoing
drug development and discovery programs that leverage its expertise in
kinase inhibitors. GPC Biotech AG is headquartered in
Martinsried/Munich (Germany). The Company's wholly owned U.S.
subsidiary has sites in Waltham, Massachusetts and Princeton, New
Jersey.

Company:                          Hana Biosciences, Inc.
Ticker Symbol & Exchange:         NASDAQ: HNAB
Investor Relations Contact:       John Iparraguirre
Investor Relations Contact Phone: [phone]
Web:                              http://www.hanabiosciences.com
Date of Presentation:             Monday, May 15, 2006

Hana Biosciences (NASDAQ: HNAB) acquires, develops, and commercializes
innovative products to advance cancer care. By collaborating with
academia and research institutions, Hana identifies development stage
product candidates that address unmet oncological needs. Using an
experienced biopharmaceutical management team, Hana moves these unique
product candidates through translational research for timely transfer
from the lab to the clinical development. Multiple technologies with
well-validated mechanisms of action and strong intellectual property
rights set the platform for accelerated growth and speeds
commercialization.

Hana Bisociences is pleased to present at the Rodman and Reshaw
Conference on May 15, 2006 at 8:40AM in the Atlantique Salon-Eastern.
A webcast can be accessed on the investor relations page at
www.hanabiosciences.com.

Company:                          GTC Biotherapeutics
Ticker Symbol & Exchange:         GTCB    NASDAQ
Investor Relations Contact:       Tom Newberry
Investor Relations Contact Phone: [phone]
Web:                              www.gtc-bio.com
Date of Presentation:             May 15, 2006

GTC Biotherapeutics is a leader in the development, production, and
commercialization of therapeutic proteins through transgenic animal
technology. In addition to GTC's lead product ATryn(R), the company is
developing a recombinant human alpha-1 antitrypsin, a recombinant
human albumin, a CD137 antibody to stimulate the immune system as a
potential treatment for solid tumors, and a malaria vaccine. GTC also
enters into partnering arrangements, or external programs, in which
its technology is used to develop transgenic production of its
partners' proprietary products, including both large-volume protein
therapeutics as well as products that are difficult to produce in
significant quantities from conventional recombinant production
systems.

Company:                          Hollis-Eden Pharmaceuticals, Inc.
Ticker Symbol & Exchange:         NASDAQ: HEPH
Investor Relations Contact:       Scott Rieger
Investor Relations Contact Phone: [phone]
Web:                              www.holliseden.com
Date of Presentation:             May 16

Hollis-Eden Pharmaceuticals is developing a proprietary new class of
small molecule compounds that are metabolic conversion products or
synthetic analogs of adrenal steroid hormones. These compounds have
been demonstrated in humans to possess several properties with
potential therapeutic benefit - they regulate innate and adaptive
immunity, reduce nonproductive inflammation and stimulate cell
proliferation. The Company's lead product candidate, NEUMUNE, is
entering late-stage development for the treatment of Acute Radiation
Syndrome, a life-threatening condition resulting from exposure to
radiation following a nuclear or radiological incident. Hollis-Eden
also is profiling second-generation compounds for potential clinical
development in a broad spectrum of therapeutic categories.

Company:                          Jerini AG
Ticker Symbol & Exchange:         JI4
Investor Relations Contact:       Stacy Wiedenmann
                                  [e-mail]
Investor Relations Contact Phone: [phone]
Web:                              www.jerini.com
Date of Presentation:             May 16th, 2006

Jerini is a pharmaceutical company based in Berlin, Germany, focusing
on the discovery and development of novel peptide-based drugs. The
company selectively pursues disease indications for which patients
have limited or no treatment options. Jerini's lead drug candidate,
Icatibant, is currently in Phase III clinical trials in Europe, the
United States, and other countries for the subcutaneous treatment of
hereditary angioedema (HAE). The next most advanced compound is JSM
6427 for the treatment of age-related macular degeneration (AMD).
Jerini's proprietary P2D discovery platform has been the basis for the
development of these drugs.

Company:                          Immtech Pharmaceuticals, Inc
Ticker Symbol & Exchange:         AMEX: IMM
Investor Relations Contact:       F. C. Thompson
Investor Relations Contact Phone: [phone]
Web:                              http://www.immtechpharma.com
Date of Presentation:             May 16, 2006

Immtech Pharmaceuticals is focused on advancing the development and
commercialization of oral drugs to treat infectious diseases and other
disorders with significant unmet needs. Immtech is in late-stage
clinical trials with its first compound, pafuramidine maleate (DB289),
for malaria, Pneumocystis pneumonia (PcP), and African sleeping
sickness (trypanosomiasis). Immtech is also in drug development
programs with other compounds for treating fungal infections and
tuberculosis. Immtech holds exclusive worldwide licenses to patents,
patent applications, and technology for products derived from a
proprietary pharmaceutical platform.

Company:                          Insmed Inc.
Ticker Symbol & Exchange:         NASDAQ: INSM
Investor Relations Contact:       Tim Ryan
Investor Relations Contact Phone: [phone]
Web:                              www.insmed.com
Date of Presentation:             Monday, May 15

Insmed is a biopharmaceutical company focused on the development and
commercialization of drug candidates for the treatment of metabolic
diseases and endocrine disorders with unmet medical needs. For more
information, please visit www.insmed.com. The company's leading
product, IPLEX was approved as an orphan drug by the United States
Food and Drug Administration in December 2005 for the treatment of
growth failure in children with severe primary IGF-I deficiency
(Primary IGFD) or with growth hormone (GH) gene deletion who have
developed neutralizing antibodies to GH.

Company:                          INYX, INC.
Ticker Symbol & Exchange:         IYXI: OTCBB
Investor Relations Contact:       Jay M. Green, Executive VP
Investor Relations Contact Phone: [phone]
Web:                              www.inyxgroup.com
Date of Presentation:             May 16, 2006

Inyx, Inc. is a specialty pharmaceutical company with niche drug
delivery technologies and products. Inyx provides its development and
production expertise to other pharmaceutcial companies on both a
consulting and collaboration basis. In addition, Inyx is developing
its own proprietary products. On April 3, 2006, Inyx announced that it
reached an agreement in principle to acquire a German pharmaceutical
production business from a pan-European specialty pharmaceutical
company, with which it is also entering into a strategic, 10-year-plus
collaboration agreement, whereby Inyx will become the exclusive
manufacturing resource for the European company's therapeutic
products. The acquisition, which is subject to completion of customary
due diligence and execution of definitive documents , is expected to
be completed by June 30, 2006.

Company:                          Javelin Pharmaceuticals, Inc.
Ticker Symbol & Exchange:         OTC: JVPH.OB
Investor Relations Contact:       Donna LaVoie / June Gregg
Investor Relations Contact Phone: [phone]
Web:                              www.javelinpharmaceuticals.com
Date of Presentation:             Monday, May 15, 2006

Javelin's product candidates address the acute moderate-to-severe pain
medication market segment. We are developing differentiated pain
control products that provide the flexibility and versatility required
to address the limitations of existing prescription pain medications.
Our product candidates offer enhanced pain relief, fewer adverse side
effects and faster relief of pain compared to other currently
available treatments. Javelin has three late stage product candidates
in development: Dyloject(TM) (diclofenac sodium, injectable),
Rylomine(TM) (intranasal morphine) and PMI-150 (intranasal ketamine).

Company:                          Lorus Therapeutics Inc
Ticker Symbol & Exchange:         AMEX:LRP & TSX:LOR
Investor Relations Contact:       Grace Tse
Investor Relations Contact Phone: [phone] x 380
Web:                              www.lorusthera.com

Lorus is a biopharmaceutical company focused on the research and
development of cancer therapies. The Company develops new drugs that
can be used, either alone or in combination, to successfully manage
cancer. Through its own discovery efforts and an in-licensing and
acquisition program, the Company is building a portfolio of anticancer
drugs with low toxicities.

Lorus has just completed a Phase III clinical trial, has eight Phase
II clinical trials in seven cancer indications underway, and a strong
preclinical drug program that is scheduled to bring a novel small
molecule technology into clinical trial.

Company:                          Manhattan Pharmaceuticals, Inc.
Ticker Symbol & Exchange:         AMEX: MHA
Investor Relations Contact:       Michelle Carroll
Investor Relations Contact Phone: [phone]
Web:                              www.manhattanpharma.com
Date of Presentation:             Tuesday, 16 May 2006

Manhattan Pharmaceuticals, Inc. (AMEX: MHA), a development stage
pharmaceutical company, acquires and develops proprietary prescription
drugs for large, underserved patient populations. In view of the
worldwide obesity epidemic, the company is developing OE, an orally
administered novel therapeutic for weight loss. To meet the needs of
other major, underserved medical markets while lowering development
risks, Manhattan Pharmaceuticals is also developing PTH (1-34), a
peptide believed to be a regulator of epidermal cell growth, for
psoriasis and Propofol Lingual Spray, a convenient, proprietary
lingual spray formulation of propofol, the world's best-selling
general anesthetic, as a sedative-hypnotic for use during diagnostic
and therapeutic procedures.

Company:                          MEDICURE INC.
Ticker Symbol & Exchange:         AMEX: MCU & TSX: MPH
Investor Relations Contact:       HOGAN MULLALLY
Investor Relations Contact Phone: [phone]
Web:                              www.medicure.com
Date of Presentation:             MAY 15, 2006

Medicure is a cardiovascular focused drug development company. The
Company's lead drug is a novel cardioprotectant called MC-1. MC-1 is
set to commence pivotal Phase III testing for ischemic reperfusion
injury, a common adverse event following restoration of blood flow
post cardiac interventions such as CABG surgery and balloon
angioplasty. There are currently no approved therapies to protect the
heart from ischemic reperfusion injury, and MC-1 is the most advanced
compound targeting the area. MC-1 has received FDA Fast Track
Designation.

Company:                          Medivation, Inc.
Ticker Symbol & Exchange:         MDV (AMEX)
Investor Relations Contact:       Patrick Machado
Investor Relations Contact Phone: [phone] x201
Web:                              www.medivation.com
Date of Presentation:             May 15, 2006

Medivation, Inc. acquires promising pharmaceutical and medical device
technologies in the late preclinical development phase, develops those
technologies quickly and cost-effectively through human first
proof-of-efficacy studies (generally the end of Phase 2 clinical
trials), and seeks to sell or partner successful programs with larger
pharmaceutical, biotechnology and medical device companies for
late-stage clinical studies and commercialization. Medivation's
current portfolio consists of small molecule drugs in development to
treat 3 large, unmet medical needs - Alzheimer's disease, Huntington's
disease and hormone-refractory prostate cancer, the last two of which
are likely Orphan Drug indications.

Company:                          MIGENIX Inc.
Ticker Symbol & Exchange:         TSX: MGI; OTC: MGIFF
Investor Relations Contact:       Arthur Ayres, CFO
Investor Relations Contact Phone: [phone] ext.233
Web:                              www.migenix.com
Date of Presentation:             Tuesday, May 16th (9:45am)

MIGENIX Inc. is committed to advancing therapy, improving health, and
enriching life by developing and commercializing drugs in the areas of
infectious and degenerative diseases. The Company's clinical programs
include drug candidates for the prevention of catheter-related
infections (Phase III), the treatment of chronic hepatitis C virus
(HCV) infections (Phase II), and the treatment of neurodegenerative
diseases (Phase I) and the treatment of acne (Phase II). MIGENIX is
headquartered in Vancouver, British Columbia, Canada with US
operations in San Diego, California.

Company:                          MorphoSys AG
Ticker Symbol & Exchange:         FSE: MOR (Germany)
Investor Relations Contact:       Dr. Claudia Gutjahr-LOser
Investor Relations Contact Phone: [phone]
Web:                              www.morphosys.com
Date of Presentation:             May 15, 2006

MorphoSys is one of the world's leading biotechnology companies
focusing on fully human antibodies. With its proprietary technologies,
MorphoSys is developing not only the next generation of therapeutic
antibodies, but also antibodies for research and diagnostics purposes.
HuCAL(R) (Human Combinatorial Antibody Library) is a very powerful
technology for the rapid and automated production of specific
antibodies. The most distinctive feature of the library is the
capability to optimize fully human antibodies to pre-defined
specifications, allowing MorphoSys researchers and their partners to
"Engineer the Medicines of Tomorrow". MorphoSys's goal is to establish
HuCAL as the technology of choice for antibody generation in all
market sectors.

Company:                          Neurobiological Technologies, Inc.
Ticker Symbol & Exchange:         NTII  NASDAQ
Investor Relations Contact:       Cheryl Schneider, VP
Investor Relations Contact Phone: Porter, LeVay & Rose, Inc.
                                  212-564-4700
Web:                              www.ntii.com
Date of Presentation:             Tuesday, May 16, 2006 at 9:45 a.m.

Neurobiological Technologies, Inc.is a drug development company
focused on the clinical evaluation and regulatory approval of
neuroscience drugs. The company's strategy is to in-license and
develop early- and later-stage drug candidates that target major
medical needs and which can be rapidly commercialized. NTI's
experienced management team oversees the human clinical trials
necessary to establish preliminary evidence of efficacy. We anticipate
that we will continue to acquire and develop late-stage neurologic
drug candidates and will develop the resources to market these drugs
in selected world regions. Our goal is to develop and market drug
candidates in the United States, Europe and Asia and we may seek
partnerships with pharmaceutical and biotechnology companies to assist
us.

Company:                          Neuromed Pharmaceuticals
Investor Relations Contact:       Bruce Colwill, CFO
Investor Relations Contact Phone: [phone]
Web:                              www.neuromed.com
Date of Presentation:             May 16, 2006

Neuromed is a privately held biopharmaceutical company developing the
next generation of chronic pain drugs with pipeline programs in
anxiety, epilepsy and cardiovascular disease such as hypertension.
Located in Vancouver, Canada and Conshohocken, USA, the Company's drug
development programs are designed around validated clinical targets
associated with large unmet markets. Neuromed exclusively focuses on
calcium channels as drug targets and is the first company to take an
orally available drug selectively targeting neuronal calcium channels
into human clinical trials.

Company:                          Newron Pharmaceuticals SpA
Web:                              www.newron.com
Date of Presentation:             15th May

Newron Pharmaceuticals SpA is a clinical stage biopharmaceutical
company focused on the discovery and development of small molecule
drugs for the treatment of central nervous system (CNS) diseases. Our
clinical focus is on neurology and pain.Through continuous research,
diligent scientific breakthroughs and ethical use of emerging new
technology, Newron Pharmaceuticals aims to provide patients with
debilitating CNS disorders effective therapies that significantly
improve their quality of life.

Newron now has two compounds in clinical trials for three indications:
safinamide in Phase III for the treatment of Parkinson's disease and
in Phase II for the treatment of Restless Legs Syndrome; and
Ralfinamide, a novel compound for the treatment of neuropathic pain in
Phase II. Additional projects are in the preclinical phase.

Company:                          Novelos Therapeutics, Inc.
Ticker Symbol & Exchange:         NVLT OTCBB
Investor Relations Contact:       Stephen Lichaw
Investor Relations Contact Phone: [phone]
Web:                              www.novelos.com
Date of Presentation:             Monday, May 15, 2006.  9:45am.

Novelos Therapeutics, Inc. is a biotechnology company commercializing
oxidized glutathione-based compounds for the treatment of cancer and
hepatitis. NOV-002, the lead compound currently in Phase 3 development
for lung cancer, is designed to act as a chemoprotectant and an
immunomodulator. NOV-002 is also being developed to treat
chemotherapy-resistant ovarian cancer and acute radiation injury.
NOV-205, a second compound, is designed to act as a hepatoprotective
agent with immunomodulating and antiinflammatory properties. Novelos
plans to initiate a U.S.-based NOV-205 clinical trial for chronic
hepatitis C by mid-2006. Both compounds have completed clinical trials
in humans and have been approved for use in the Russian Federation
where they were originally developed. For additional information about
Novelos please visit www.novelos.

Company:                          NovaDel Pharma, Inc.
Ticker Symbol & Exchange:         NVD
Investor Relations Contact:       MacDougall Biomedical Comm.
Investor Relations Contact Phone: Chris Erdman, 508-647-0209 X14
Web:                              www.novadel.com
Date of Presentation:             May 16, 2006

NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in
the development of novel drug delivery systems for prescription and
over-the-counter drugs. The Company's proprietary lingual spray
technology delivery system offers the patient the potential for (i)
fast onset of action; (ii) improved drug safety by reducing the
required drug dosage and reducing side effects; (iii) improved patient
convenience and compliance; and (iv) enhanced dosage reliability. The
Company plans to develop such products independently and through
collaborative arrangements with major pharmaceutical and biotech
companies.

Company:                          Oncolytics Biotech Inc.
Ticker Symbol & Exchange:         ONC:TSX, ONCY:NASDAQ
Investor Relations Contact:       Cathy Ward
Investor Relations Contact Phone: [phone]
Web:                              www.oncolyticsbiotech.com
Date of Presentation:             Tuesday, May 16 at 11:55 a.m.

Oncolytics Biotech Inc. is focused on the development of oncolytic
viruses as a novel and effective approach to cancer treatment.
Oncolytics' lead product, REOLYSIN(R), is developed from the human
reovirus. Oncolytics has completed three human clinical studies with
REOLYSIN(R) in Canada and is currently conducting or has permission to
conduct another four clinical studies in the U.S. and the U.K. Interim
and final results of the first five clinical studies for a variety of
advanced cancers have demonstrated evidence of tumour regression with
only minor side effects such as mild, flu-like symptoms of short
duration.

Company:                          Orexo AB (publ)
Ticker Symbol & Exchange:         SSE-ORX
Investor Relations Contact:       Zsolt Lavotha (CEO)
Investor Relations Contact Phone: [phone]
Web:                              www.orexo.com
Date of Presentation:             Monday May 15

Orexo is a pharmaceutical company that focuses on developing new
pharmaceutical drugs within areas currently subject to considerable
clinical needs. Orexo's products are based on existing pharmaceuticals
and the company's patented drug-delivery technologies. Orexo applies
its broad expertise in medicine and pharmacy to the further
development of existing pharmaceutical substances. By combining
well-documented compounds with its own patented drug-delivery methods
and its unique expertise in "dry formulations" (for example, tablets),
Orexo is able to develop new patented pharmaceuticals.

At present, the company has one product on the market, three under
clinical development, one of which has been out-licensed in the US,
Europe and Japan, two projects in the pharmaceutical formulation
phase, and one project in an early development stage.

Company:                          PAION AG
Ticker Symbol & Exchange:         PA8 FSE
Investor Relations Contact:       Dr. Peer Nils Schroder
Investor Relations Contact Phone: [phone]
Web:                              www.paion.de
Date of Presentation:             15.5.2006, 4.55 p.m.

PAION, a biopharmaceutical company based in Aachen, Germany, aims to
become a leader in developing and commercialising innovative drugs for
the treatment of stroke and other thrombotic diseases for which there
is a substantial unmet medical need. PAION intends to build an
integrated drug portfolio by exploiting its expertise in identifying
compounds, licensing or otherwise acquiring them and advancing them
through the clinical development and regulatory approval process.
PAION's lead product Desmoteplase for the treatment of acute ischaemic
stroke is currently in Phase III. Two additional drugs are in clinical
development. At the end of 2005, PAION employed 72 people.

Company:                          Panacos Pharmaceuticals Inc.
Ticker Symbol & Exchange:         PANC (NASDAQ)
Investor Relations Contact:       Jill Smith
Investor Relations Contact Phone: [phone]
Web:                              http://www.panacos.com
Date of Presentation:             May 16

Panacos is developing the next generation of anti-infective products
through discovery and development of small molecule oral drugs for the
treatment of HIV and other major human viral diseases. Panacos' lead
candidate, PA-457, is the first in a new class of oral HIV
therapeutics under development called maturation inhibitors,
discovered by Panacos scientists and their academic collaborators. By
targeting a novel step in the virus life cycle, maturation inhibitors
are designed to have potent activity against a broad range of HIV,
including strains that are resistant to existing classes of drugs.
Panacos' proprietary discovery technologies focus on novel targets in
the virus life cycle, including virus maturation and virus fusion.

Company:                          Prana Biotechnology Limited
Ticker Symbol & Exchange:         ASX:PBT / Nasdaq: PRAN
Investor Relations Contact:       Kathy Price
Investor Relations Contact Phone: The Global Consulting Group,
                                  646-284-9430
Web:                              www.pranabio.com
Date of Presentation:             May 16, 2006

Prana Biotechnology discoveries, emerging out of MGH at Harvard and
the University of Melbourne in Australia, have lead to the development
of MPAC's (Metal Protein Attenuating Compounds), which have shown
great promise to treat a variety of neurodegenerative disorders.
Clinical efficacy (phase 2) was demonstrated in a 'proof of principle'
MPAC (PBT1) for Alzheimer's disease. Prana's lead proprietary
molecule, PBT2, has successfully completed Phase 1 testing for AD.
Furthermore, very encouraging research findings were published
demonstrating the efficacy of MPAC's in pre-clinical models of
Parkinson's Disease, Huntington's Disease and certain cancers. All of
these represent potential therapeutic targets for Prana.

Company:                          Pro-Pharmaceuticals, Inc.
Ticker Symbol & Exchange:         PRW:  Amex
Investor Relations Contact:       Tony Squeglia
Investor Relations Contact Phone: [phone]
Web:                              www.pro-pharmaceuticals.com
Date of Presentation:             May 15

Pro-Pharmaceuticals is a development stage company engaged in the
discovery, development, and commercialization of carbohydrate-based
therapeutic compounds. The Company's expertise offers opportunities to
provide advanced treatment of cancer, liver, microbial, cardiovascular
and inflammatory disease, and viral infections. The Company has
initially focused on target delivery of chemotherapy drugs for the
treatment of cancer. DAVANAT(R), the Company's lead product candidate,
when used with FDA-approved cancer drugs, may increase the efficacy
and decrease the toxicity of current chemo treatments. DAVANAT(R) with
5-FU completed a Phase I trial for all solid tumors and is currently
in a Phase II colorectal cancer trial. The Company has initiated a
Europe-based Phase III colorectal cancer trial and a Phase II trial
for bile duct cancer.

Company:                          Proteome Systems Ltd
Ticker Symbol & Exchange:         PXL/ASX
Investor Relations Contact:       Lisa Jones
Investor Relations Contact Phone: [phone]
Web:                              www.proteomesystems.com
Date of Presentation:             15 May 2006

Proteome Systems Limited is an Australian based biotechnology company
which discovers and develops diagnostic and therapeutic products. The
Company has extensive expertise in the discovery and development of
protein biomarkers and their subsequent development for diagnostic
use. Our focus is on respiratory disease, neurodegenerative disease,
cancer and infectious diseases.

The Company's lead diagnostic programmes are Tuberculosis, Prostate
Cancer, Ovarian Cancer and Huntington's Disease. Our lead therapeutic
programmes are for radiation damage, topical disease and novel
antibiotic targets.

Company:                          Provectus Pharmaceuticals
Ticker Symbol & Exchange:         PVCT.ob
Investor Relations Contact:       Matt Clawson @ Allen & Caron
Investor Relations Contact Phone: [phone]
Web:                              www.pvct.com
Date of Presentation:             May 16, 2006

Provectus Pharmaceuticals, Inc. is an innovative biopharmaceutical
company engaged in the design, development and marketing of
pharmaceutical technologies for the treatment of psoriasis, breast
cancer, liver cancer and metastatic melanoma. The Company has
developed core technologies and intellectual properties surrounding
Rose Bengal ("PV-10"), a stable, non-toxic substance that has
traditionally been used as an imaging agent in medicine. Provectus is
preparing to begin Phase 2 clinical trials for Xantryl(TM), a topical
treatment for psoriasis. In oncology, the Company has developed
Provecta(TM) for the treatment of metastatic melanoma and recurrent
breast cancer. Provecta is currently undergoing Phase 1 clinical
trials.

Company:                          Questcor Pharmaceuticals, Inc.
Ticker Symbol & Exchange:         QSC: AMEX
Investor Relations Contact:       Eric Liebler, Nisola, LLC
                                  [e-mail]
Investor Relations Contact Phone: [phone]
Web:                              www.questcor.com
Date of Presentation:             05/15/06

Questcor Pharmaceuticals, Inc.(R) (AMEX: QSC) is a specialty
pharmaceutical company that develops and commercializes novel
therapeutics for the treatment of neurological disorders. Questcor
currently markets H.P. Acthar(R) Gel (repository corticotropin
injection), an injectable drug indicated for the treatment of
exacerbations associated with Multiple Sclerosis and Doral(R)
(quazepam) that is indicated for the treatment of insomnia,
characterized by difficulty in falling asleep, frequent nocturnal
awakenings, and/or early morning awakenings. For more information,
please visit www.questcor.com.

Company:                          Serono International S.A.
Ticker Symbol & Exchange:         SEO / SRA
Investor Relations Contact:       Robert Bennett. [phone]
Web:                              www.serono.com
Date of Presentation:             May 15th, 2006 at 10.30 AM

Serono is a global biotechnology leader. The Company has eight
biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R)/
Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R). In
addition to being the world leader in reproductive health, Serono has
strong market positions in neurology and growth & metabolism and has
recently entered the psoriasis area. The Company's research programs
are focused on growing these businesses and on establishing new
therapeutic areas, including oncology and autoimmune diseases.
Currently, there are more than 25 ongoing preclinical and clinical
development projects. In 2005, Serono, whose products are sold in over
90 countries, achieved worldwide revenues of US$2,586.4 million.

Company:                          Spectrum Phamaceuticals, Inc.
Ticker Symbol & Exchange:         SPPI
Investor Relations Contact:       Jeanie D. Herbert
Investor Relations Contact Phone: [phone]
Web:                              www.spectrumpharm.com
Date of Presentation:             May 16, 9:25 - 9:45 a.m. (EURO)

Spectrum Pharmaceuticals, Inc. is a specialty pharmaceutical company
based in Irvine, California, engaged in the business of acquiring,
developing and commercializing prescription drug products for the
treatment of cancer and other unmet medical needs. Spectrum has built
a diversified portfolio of proprietary and generic drug products in
various stages of development and regulatory approval. For more
information, please visit our website at www.spectrumpharm.com.

Company:                          SR Pharma plc. / Atugen AG
Ticker Symbol & Exchange:         SPA.L (AIM)
Investor Relations Contact:       Thomas Christely (CEO/Atugen)
Investor Relations Contact Phone: [phone]
Web:                              www.srpharma.com & www.atugen.com
Date of Presentation:             15 May 2006

SR Pharma plc. is a European biopharmaceutical company based in the UK
and Germany and listed on AIM, London. In June 2005 SR Pharma plc has
acquired Atugen AG, Berlin, Germany, a leader in RNAi therapeutics.
Atugen owns novel, chemically modified proprietary short interfering
RNA (siRNA) molecules (AtuRNAi) and a proprietary in vivo delivery
system (AtuPLEX) which both have several advantages over conventional
siRNA molecules and their delivery. Clinical development of AtuRNAi
therapeutic molecules are targeted to start in H1/2007 for systemic
applications in advanced cancers. Several AtuRNAi candidates are in
pre-clinical development with a corporate partner for other
therapeutic indications.

Company:                          Sunesis Pharmaceuticals, Inc.
Ticker Symbol & Exchange:         SNSS
Investor Relations Contact:       Eric Bjerkholt
Investor Relations Contact Phone: [phone]
Web:                              www.sunesis.com
Date of Presentation:             May 15, 2006 @ 11:15AM

Sunesis is a clinical-stage biopharmaceutical company focused on the
discovery, development and commercialization of novel small molecule
therapeutics for oncology and other serious diseases. Sunesis has
built a broad product candidate portfolio through internal discovery
and in-licensing of novel cancer therapeutics. Sunesis is advancing
its product candidates through in-house research and development
efforts and strategic collaborations with leading pharmaceutical and
biopharmaceutical companies.

Company:                          Tactical Therapeutics Inc
Investor Relations Contact:       Rashida A. Karmali, J.D., Ph.D
Investor Relations Contact Phone: [phone]
Web:                              www.tacticaltherapeutics.com
Date of Presentation:             May 16, 2006

Tactical Therapeutics, Inc. has developed a patented cancer
therapeutic that has unique pharmacokinetic properties of faster
delivery to target cancer cells and a high clearance rate and reduced
toxicity. Specifically, Tactical's drug candidate, CAI Orotate
(CAI-O), has overcome all of the disadvantages of a related Merck
Inc's discontinued drug- CAI. Tactical has been advised by the FDA to
develop CAI-O under the Accelerated Drug Approval Track. The time line
is to file the IND in 2007 and the NDA in 2010. Tactical has focused
on its drug discovery efforts on therapies that are more effective,
less toxic and more cost effective than currently available. Some
"targeted" cancer treatments (biologics-AVASTIN) are reducing cancer
deaths, but are expensive. Tactical's CAI-O is equally effective in
preclinical models but also cost-effective.

Company:                          Threshold Pharmaceuticals, Inc.
Ticker Symbol & Exchange:         THLD : NASDAQ
Investor Relations Contact:       Denise Powell
Investor Relations Contact Phone: [phone]
Web:                              www.thresholdpharm.com
Date of Presentation:             May 15, 2006

Threshold is a biotechnology company focused on the discovery,
development and commercialization of small molecule therapeutics in
middle- and late- stage clinical trials for the potential treatment of
benign prostatic hyperplasia (BPH), a disease afflicting tens of
millions of men worldwide, and cancer. By selectively targeting tumor
or other abnormally-proliferating cells, the Company's drug candidates
are designed to be potentially more effective and less toxic to
healthy tissues than conventional treatments. For additional
information, please visit our website: http://www.thresholdpharm.com

Company:                          Xenomics, Inc.
Ticker Symbol & Exchange:         XNOM.OB & XE7
Investor Relations Contact:       Dr. L. David Tomei, Ph.D.
Investor Relations Contact Phone: [phone]
Web:                              www.xenomics.com
Date of Presentation:             May 15, 2006

Xenomics is a molecular diagnostic company that has developed a
non-invasive, DNA-based urine analysis technology which may be
utilized for the detection and monitoring of a wide range of medical
subjects including infectious diseases, cancers, prenatal conditions,
and others.

Xenomics' patented proprietary technology utilizes this fragmented DNA
material which has crossed the kidney barrier ("Trans-Renal DNA" or
"Tr-DNA") and is available in urine to provide vital information about
conditions throughout the body.

Xenomics' immediate product focus is in the area of infectious
diseases, specifically tuberculosis, and prenatal conditions. The
Company plans to launch is first products in these areas in 2007-2008.

Company:                          YM BioSciences Inc.
Ticker Symbol & Exchange:         TSX: YM; AMEX: YMI; AIM: YMBA
Investor Relations Contact Phone: [phone]
Web:                              www.ymbiosciences.com
Date of Presentation:             May 15/06

YM BioSciences Inc. is a cancer product development company
established in Canada in 1994. Its shares are listed on the American
Stock Exchange, the London Stock Exchange's AIM and the Toronto Stock
Exchange. YM was named one of "Canada's Top 10 Life Sciences
Companies" by the Ottawa Life Sciences Council in November 2005.

YM BioSciences licenses research products from academic institutions
and other biotechnology companies and then focuses on developing these
products. Its current clinical development portfolio includes four
different anti-cancer products in a number of formulations targeting
10 tumour types as well as novel delivery of opioids for cancer pain.
YM BioSciences is advancing drugs through Phase III, II, I/II and also
has a number if compounds in pre-clinical development.

Company:                          York Pharma plc
Ticker Symbol & Exchange:         YRK London Exchange
Investor Relations Contact:       Rowan Minion, Northbank Commun
Investor Relations Contact Phone: [phone]
Web:                              http://www.YorkPharma.com
Date of Presentation:             16 May 2006

York Pharma is a speciality pharmaceutical company aimed at
discovering, acquiring, developing and commercialising novel and
superior prescription dermatological products.

The Company's portfolio consists of six first in class products
addressing the important anti-fungal, psoriasis, eczema and acne
markets that collectively make up 75% of the $10.4bn global
prescription dermatology market.

Abasol, the Company's lead antifungal product offers features and
benefits that York believes will give it a significant competitive
advantage in a $2.4bn market. The Company is preparing for its first
regulatory approval and commercialisation in Europe in 2006.

With Vampex and Sabarep progressing through clinical development for
psoriasis and eczema respectively, York is poised to make a
significant impact in dermatology.

Company:                          ZIOPHARM Oncology, Inc.
Ticker Symbol & Exchange:         ZIOP.OB
Investor Relations Contact:       Suzanne McKenna
Investor Relations Contact Phone: [phone]
Web:                              www.ziopharm.com
Date of Presentation:             Tueday May 16, 2006

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the
development and commercialization of a diverse, risk-sensitive
portfolio of in-licensed cancer drugs to address unmet medical needs.
The Company applies new insights from molecular and cancer biology to
understand the efficacy and safety limitations of approved and
developmental cancer therapies and identifies proprietary and related
molecules for better patient treatment. For more information, visit
www.ziopharm.com.

Note to Editors: Business Wire's PressPass allows you to create free, custom Web, RSS, and email-based news feeds from more than 160 industry options, dozens of subject categories and thousands of geographic preferences as well as by specific company filters. In addition, PressPass subscribers have access to exclusive content, experts, company profiles, survey services and other media services.

Note to Event Organizers: Add your trade show, conference, or event to www.tradeshownews.com, Business Wire's online event calendar. For information, email [e-mail].